JORGE CASTILLO to Bortezomib
This is a "connection" page, showing publications JORGE CASTILLO has written about Bortezomib.
Connection Strength
2.040
-
Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. Br J Haematol. 2019 02; 184(4):679-682.
Score: 0.582
-
Bortezomib in plasmablastic lymphoma: A glimpse of hope for a hard-to-treat disease. Leuk Res. 2017 11; 62:12-16.
Score: 0.564
-
Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024 08; 99(8):1586-1594.
Score: 0.223
-
Does Bortezomib-Dexamethasone-Rituximab-Cyclophosphamide Play a Role in the Treatment of Waldenstr?m's Macroglobulinemia? J Clin Oncol. 2023 08 20; 41(24):4059-4060.
Score: 0.210
-
Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. Blood. 2018 12 13; 132(24):2608-2612.
Score: 0.152
-
Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma. Br J Haematol. 2015 May; 169(3):352-5.
Score: 0.117
-
Biology, prognosis, and therapy of Waldenstr?m Macroglobulinemia. Cancer Treat Res. 2015; 165:177-95.
Score: 0.117
-
Plasmablastic lymphoma transformation in a patient with Waldenstr?m macroglobulinemia treated with ibrutinib. Br J Haematol. 2021 11; 195(3):466-468.
Score: 0.046
-
Cyclophosphamide, bortezomib, and dexamethasone combination in waldenstrom macroglobulinemia. Am J Hematol. 2015 Jun; 90(6):E122-3.
Score: 0.030